China News Agency, Beijing, January 18th (Reporter Li Chun) According to news from the National Medical Security Administration of China on the 18th, two new crown treatment drugs, such as Azivudine Tablets and Qingfei Paidu Granules, will be officially included in the national medical insurance drugs after a price reduction through negotiations. Table of contents.
At the press conference of the National Medical Insurance Administration held on the same day, Huang Xinyu, deputy director of the Medical Service Management Department of the National Medical Insurance Administration, said that most of the newly added drugs in the National Medical Insurance Drug List adjustment in 2022 are newly listed drugs within five years. 23 drugs were launched in 2022 and were included in the catalog that year.
According to the press conference, this adjustment fully supports the treatment of new crown virus infection. Included in the National Medical Insurance Drug Catalog.
Among the 25 marketed drugs involved in the tenth edition of the new coronavirus infection diagnosis and treatment plan, 21 varieties have been officially included in the national medical insurance catalog.
In addition, catalog adjustments continue to support the entry of drugs in key areas into the catalog.
Support domestically produced major innovative drugs to be included in the catalog. This time, a total of 24 domestically produced major innovative drugs were included in the negotiations, and finally 20 drugs such as Orebatinib were successfully negotiated.
At the same time, 7 drugs for rare diseases, 22 drugs for children, and 2 essential drugs have been successfully included in the catalog, and the level of drug protection in key areas has been further improved.
Huang Xinyu said that the new crown epidemic is still continuing, and the National Medical Insurance Bureau will implement a guarantee policy for the treatment expenses of patients infected with the new crown virus.
"Recently, we have noticed that there may be some domestic and foreign COVID-19 treatment drugs that have been approved for marketing one after another. The number of drug options for COVID-19 treatment is gradually increasing, the competition is gradually strengthening, and the room for medical insurance policy adjustments is also expanding accordingly. We will pay close attention to the progress of drug research and development and marketing. , to guide the reasonable formation of new crown treatment drug prices." (End)